The TAILORx trial included patients treated between 2006 and 2010, thus more accurately reflecting improved prognosis for hormone receptor–positive breast cancer after the year 2000.9 We also report external validation of this new tool for estimation of DR risk in an independent cohort of 1,098 women with node-negative disease from the Clalit Health Services registry.10 This evidence concerns the gene NR4A1 and breast carcinoma.